Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Comment by EternalPonzion Jan 15, 2021 11:15am
198 Views
Post# 32305960

RE:RE:RE:9 billion

RE:RE:RE:9 billion
Negative, no short. No skin in this game anymore. I was very tempted to though when I saw it climb to over $1 so quickly. It was 100% guaranteed to pull back regardless of headline risk. On that topic, yes the pumpers are out in full force. Yahoo Finance is a classic example. The Outrageously bullish comments based on no facts have a permanent placeholder near the top of the board. I tried placing some a comments to restore some sanity to the board but do you think those comments ever appeared? Not just this stock either. This shows that the market is rigged now more so than ever. There is definite collusion ongoing now. Yahoo Finance should be investigated, but they won't be. Its unfortunate that the market has truly become a casino with a vast cadre of news players (millenials) who are desperately attempting to hit the jackpot. Most (90%) will fail. They make their bets based on very poor information. For instance ACST; 1. Is in the red zone for remaining cash, 2. Hasn't provided any meaningful updates regarding their supposedly ongoing analysis of secondary endpoints re Phase 3 trials or their supposedly ongoing strategic review. This should have been completed by now, yet no official word. Why? There was also never any update on who had been let go (not including officers) and how may employees they have remaining. 3. Has a management team that has decidedly and consistently acted in their own best interests and not the shareholder's interests and seems to be continuing to this very day. I have no doubt that they are desperately attempting to find a partner. If found, that will be their only accomplishment (not success) in how many years of operation? That deal will not be as lucrative as many are hoping but as long some 'option' value can be salvaged its all good right? Many a CEO has sold a company for far less than it should have been for personal gain. CryoCath is a perfect example. Was sold in Aug of 2008 to Medtronic for a swan. CEO made out well, the shareholders not so much. IMO (and many others) stock should have been sold for at least 50% more as it was a fantastically innovative company and was beginning to make a profit and thus some leverage. But turns out management and the board were lazy and it was much easier and more lucrative to cash out. This was the dawn of the financial crisis which is still ongoing today - millenials just don't realize it. Unfortunately ACST has virtually no leverage as I really do not believe there is an appetite to conduct another Phase 3 trial under a different protocol by any potential partner. The product is expensive to manufacture and the cost to eventually get this to market (especially as a supplement) not worth it . There are too many competing players in the field. Fact is, ACST arrived to the party far too late and by completely messing up their Ph3 trials made the situation much worse. They ran out of time long ago and are now almost out of money. There is your Strategic Review (did it in 30 secs). Its really unfortunate but one's success in business or playing the market is primarily dependent on timing. It doesn't matter how 'right' you may eventually be proven to be if the timing is missed you fail. Another reason I don't take a short position - the timing must be perfect and you better be 100% sure the reason you are going short is sound. You have to be certain (in other words have insider info).
<< Previous
Bullboard Posts
Next >>